



JFW

Certificate of Mailing (37 C.F.R. §1.8):
I hereby certify that this correspondence is being
deposited with the United States Postal Service as
First Class Mail in an envelope addressed to:
Commissioner for Patents, PO Box 1450, Alexandria,
VA 22313-1450, on this 31st day of August 2004.

s/ Rachel Potash
Rachel Potash

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re the Application of:
JUSTIN CHAPMAN, ET AL.**

Serial No.: 10/791,950

Confirmation No.: 4129

Filed: March 3, 2004

**For: DIAGNOSTICS AND THERAPEUTICS
FOR THE GENE EXPRESSION SIGNATURE
OF PPAR γ RECEPTOR LIGANDS**

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

Honorable Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. § 1.97(b) or 1.97(c)

37 CFR § 1.97(b)

- ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

37 CFR § 1.97(c)

- ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of (1) a Final Action under § 1.113; (2) a Notice of Allowance under § 1.311; or (3) an action that otherwise closes prosecution in the application. The Commissioner is hereby authorized to charge the fee as set forth in § 1.17(p) to Deposit Account Number 500329.

- ☐ Applicant requests that the Examiner consider the following copending applications:


Application Serial No.	Filing Date

- ☐ Copies of these copending applications are enclosed.
- ☒ Applicant hereby requests consideration of the Information Disclosure Statement, USPTO form 1449, submitted herewith. Copies of the cited references, except as noted below, are enclosed.
- ☐ This application is a continuation, divisional or continuation-in-part of Serial No. [REDACTED]. Copies of the cited references, if not enclosed, are available in the file of the parent application or parents thereof.
- ☒ This application was filed after June 30, 2003, or entered U.S. national stage under 35 U.S.C. § 371, after June 30, 2003. Copies of U.S. Patents and U.S. Patent Application Publications are not enclosed. (1276 OG 55).
- ☐ Applicant hereby requests consideration of the enclosed International Search Report, which was received in a related international patent application.

The Commissioner is hereby authorized to charge any fee deficiency, including any fee required under 37 C.F.R. § 1.17(p), or credit any overpayment, to Deposit Account Number 500329. A duplicate copy of this form is enclosed.

Respectfully submitted,

Date: August 31'04



Elsa Djuardi, Ph.D.
Attorney For Applicant
Registration No. 45,963

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 638-6117
Fax: (858) 678-8233



Certificate of Mailing (37 C.F.R. §1.8);
I hereby certify that this correspondence is being
deposited with the United States Postal Service as
First Class Mail in an envelope addressed to:
Commissioner for Patents, PO Box 1450,
Alexandria, VA 22313-1450 on this
31st day of August 2004.

s/ Rachel Potash
Rachel Potash

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
JUSTIN CHAPMAN, ET AL.

Serial No.: 10/791,950

Filed: March 3, 2004

For: **DIAGNOSTICS AND THERAPEUTICS
FOR THE GENE EXPRESSION SIGNATURE
OF PPAR γ RECEPTOR LIGANDS**

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

Honorable Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith are the following documents:

- | | |
|--|---------------------|
| 1. Transmittal of Information Disclosure Statement | 2 pages; |
| 2. Form PTO SB/08A | 12 pages; |
| 3. Return Postcard | 1 postcard; |
| 4. Copies of Cited References | 137 References; and |
| 5. Total Fee Due \$0.00 | Deposit Account. |

Respectfully submitted,

Date: August 31st '04

Elsa Djuardi
Elsa Djuardi, Ph.D.
Attorney For Applicants
Registration No. 45,963

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 638-6117
Fax: (858) 678-8233

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

Complete if Known

Application Number	10/791,950
Filing Date	March 3, 2004
First Named Inventor	Justin Chapman
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	PC25228A

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ²			
	AA	4,563,419	01-07-1986	RANKI, T., et al.	
	AB	4,683,202	07-28-1987	MULLIS, K., et al.	
	AC	4,683,195	07-28-1987	MULLIS, K., et al.	
	AD	4,751,177	06-14-1988	STABINSKY, Y., et al.	
	AE	5,093,246	03-03-1992	CECH, T., et al.	
	AF	5,116,742	05-26-1992	CECH, T., et al.	
	AG	5,143,854	09-01-1992	PIRRUNG, M., et al.	
	AH	5,144,019	09-01-1992	ROSSI, J., et al.	
	AI	5,225,337	07-06-1993	ROBERTSON, H., et al.	
	AJ	5,252,743	10-12-1993	BARRETT, R., et al.	
	AK	5,254,678	10-19-1993	HASELOFF, J., et al.	
	AL	5,384,261	01-24-1995	WINKLER, J., et al.	
	AM	5,412,087	05-02-1995	MCGALL, G., et al.	
	AN	5,424,186	06-13-1995	FODOR, S., et al.	
	AO	5,451,683	09-19-1995	BARRETT, R., et al.	
	AP	5,563,037	10-08-1996	SUTHERLAND, J., et al.	
	AQ	5,571,639	11-05-1996	HUBBELL, E., et al.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/791,950
Filing Date	March 3, 2004
First Named Inventor	Justin Chapman
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	PC25228A

	AR	5,593,839	01-14-1997	HUBBELL, E., et al.	
	AS	5,599,695	02-04-1997	PEASE, R., et al.	
	AT	5,624,711	04-29-1997	SUNDBERG, S., et al.	
	AU	5,631,734	05-20-1997	STERN, D., et al.	
	AV	5,677,195	10-14-1997	WINKLER, J., et al.	
	AW	5,679,647	10-21-1997	CARSON, D., et al.	
	AX	6,083,697	07-04-2000	BEECHER, J., et al.	
	AY	6,203,987	03-20-2001	FRIEND, S., et al.	
	AZ	6,263,287	07-17-2001	ZHENG, et al.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	BA	EP 0 070 685 A2	01-26-1983	Standard Oil Company		
	BB	EP 0 728 520	08-28-1996	Affymetrix Inc.		
	BC	WO 86/03782	07-03-1986	Malcolm, Alan, et al.		
	BD	WO 88/09810	12-15-1988	Synthetic Genetics		
	BE	WO 90/01564	02-22-1990	Microprobe Corporation		
	BF	WO 90/15070	12-13-1990	Affymax Technologies, N.V.		
	BG	WO 92/10092	06-25-1992	Affymax Technologies, N.V.		

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/791,950
Filing Date	March 3, 2004
First Named Inventor	Justin Chapman
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	PC25228A

	BH	WO 93/09668 (equivalent to EP 624,059)	05-27-1993	Affymax Technologies, N.V.		
	BI	WO 95/11995	05-04-1995	Affymax Technologies, N.V.		
	BJ	WO 96/17958	06-13-1996	The Regents of the University of California		
	BK	WO 97/10365	03-20-1997	Affymax Technologies, N.V.		
	BL	WO 97/17471	05-15-1997	Biometric Imaging, Inc.		
	BM	WO 97/17076	05-15-1997	Biometric Imaging, Inc.		
	BN	WO 97/19110	05-29-1997	Cancer Research Campaign Technology Limited		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BO	ALTON, et al., "Non-Invasive Liposome-Mediated Gene Delivery Can Correct the Ion Transport Defect in Cystic Fibrosis Mutant Mice," <i>Nature Genetics</i> , 1993, 135-142, Vol. 5.	
	BP	AUWERX, J., "PPAR γ , the Ultimate Thrifty Gene," <i>Diabetologia</i> , 1999, 1033-1049, Vol. 42.	
	BQ	BAUMANN, C., et al., "Activation of Glycogen Synthase by Insulin in 3T3-L1 Adipocytes Involves c-CBL-associating Protein (CAP)-dependent and CAP-independent Signaling Pathways," <i>Journal of Biological Chemistry</i> , 2001, 6065-6068, Vol. 276, No. 9.	
	BR	BELTZ, G.A., et al., <i>Methods in Enzymology</i> , Vol. 100, Part B, Wu, L., Grossman, L., Moldave, K., Eds., Academic Press, New York, Chapter 19 266-308, 1985.	
	BS	BENOIST, C., et al., "In Vivo Sequence Requirements of the SV40 Early Promoter Region," <i>Nature</i> , 1981, 304-310, Vol. 290.	
	BT	BISWAS, B., et al., "Gene Amplification by Polymerase Chain Reaction for Detection of <i>Ehrlichia Risticii</i> DNA in Potomac Horse Fever," <i>Annals of the New York Academy of Sciences</i> , 1990, 582-583, Vol. 590.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/791,950
Filing Date	March 3, 2004
First Named Inventor	Justin Chapman
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	PC25228A

BU	BISWAS, B., et al., "Diagnostic Application of Polymerase Chain Reaction for Detection of <i>Ehrlichia risticii</i> in Equine Monocytic Ehrlichiosis," <i>Journal of Clinical Microbiology</i> , Oct. 1991, 2228-2233, Vol. 29, No. 10.
BV	BOWTELL, D., et al., "Options Available – From Start to Finish – For Obtaining Expression Data By Microarray," <i>Nature Genetics (Supplement)</i> , Jan. 1999, 25-32, Vol. 21.
BW	BRINSTER, R., et al., "Regulation of Metallothionein-Thymidine Kinase Fusion Plasmids Injected Into Mouse Eggs," <i>Nature</i> , 1982, 39-42, Vol. 296.
BX	CANONICO, A., et al., "Aerosol and Intravenous Transfection of Human α 1-Antitrypsin Gene to Lungs of Rabbits," <i>American Journal of Respiratory Cell Molecular Biology</i> , 1994, 24-29, Vol. 10.
BY	CHIELLINI, C., et al., "Obesity Modulates the Expression of Haptoglobin in the White Adipose Tissue via TNF α ," <i>Journal of Cellular Physiology</i> , 2002, 251-258, Vol. 190.
BZ	CHIRGWIN, J., et al., "Isolation of Biologically Active Ribonucleic Acid from Sources Enriched in Ribonuclease," <i>Biochemistry</i> , 1979, 5294-5299, Vol. 18, No. 24.
CA	CHRISTIANSEN, M., et al., "Orosomucoid in Urine Predicts Cardiovascular and Over-All Mortality in Patients with Type II Diabetes," <i>Diabetologia</i> , 2002, 115-120, Vol. 45.
CB	CHOWRIRA, B., et al., "Extensive Phosphorothioate Substitution Yields Highly Active and Nuclease-Resistant Hairpin Ribozymes," <i>Nucleic Acids Research</i> , 1992, 2835-2840, Vol. 20, No. 11.
CC	CONNER, B.J., et al., "Detection of Sick Cell β^S -globin Allele By Hybridization With Synthetic Oligonucleotides," <i>PNAS USA</i> , January 1983, 278-282, Vol. 80.
CD	COWSERT, L.M., "In Vitro and In Vivo Activity of Antisense Inhibitors of Ras: Potential for Clinical Development," <i>Anti-Cancer Drug Design</i> , 1997, 359-371, Vol. 12.
CE	DAUBENDIEK, S., et al., "Generation of Catalytic RNAs by Rolling Transcription of Synthetic DNA Nanocircles," <i>Nature Biotechnology</i> , 1997, 273-277, Vol. 15.
CF	DEROSSI, D., et al., "The Third Helix of the Antennapedia Homeodomain Translocates Through Biological Membranes," <i>Journal of Biological Chemistry</i> , 1994, 10444-10450, Vol. 269, No. 14.
CG	DEROSSI, D., et al., "Cell Internalization of the Third Helix of the Antennapedia Homeodomain is Receptor-independent," <i>Journal of Biological Chemistry</i> , 1996, 18188-18193, Vol. 271, No. 30.
CH	DUGGAN, D., et al., "Expression Profiling Using cDNA Microarrays," <i>Nature Genetics (Supplement)</i> , 1999, 10-14, Vol. 21.
CI	DULAC, C., "Cloning of Genes from Single Neurons," <i>Current Topics in Developmental Biology</i> , 1998, 245-258, Vol. 36.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/791,950
Filing Date	March 3, 2004
First Named Inventor	Justin Chapman
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	PC25228A

CJ	EBEL, S. et al., "Very Stable Mismatch Duplexes: Structural and Thermodynamic Studies on Tandem G-A Mismatches in DNA," <i>Biochemistry</i> , 1992, 12083-12086, Vol. 31.
CK	EBERWINE, J., et al., "Analysis of Gene Expression in Single Live Neurons," <i>PNAS USA</i> , April 1992, 3010-3014, Vol. 89.
CL	ECKERT, K., et al., "DNA Polymerase Fidelity and the Polymerase Chain Reaction," <i>PCR Methods and Applications</i> , 1991, 17-24, Vol. 1.
CM	ELBASHIR, S., et al., "Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells," <i>Nature</i> , 2001, 494-498, Vol. 411.
CN	ESTERBAUER, H., et al., "Peroxisome Proliferator-Activated Receptor- γ Coactivator-1 Gene Locus, Associations With Obesity Indices in Middle-Aged Women," <i>Diabetes</i> , 2002, 1281-1286, Vol. 51.
CO	FELGNER, P., et al., "Improved Cationic Lipid Formulations for <i>In Vivo</i> Gene Therapy," <i>Annals NY Academy of Sciences</i> , 1995, 126-139, Vol. 772.
CP	FERGUSON, J., et al., "A Fiber-Optic DNA Biosensor Microarray for the Analysis of Gene Expression," <i>Nature Biotechnology</i> , 1996, 1681-1684, Vol. 14.
CQ	FODOR, S., et al., "Light-Directed, Spatially Addressable Parallel Chemical Synthesis," <i>Science</i> , 1991, 767-777, Vol. 251.
CR	FRANCKHAUSER, S., et al., "Increased Fatty Acid Re-esterification by PEPCK Overexpression in Adipose Tissue Leads to Obesity Without Insulin Resistance," <i>Diabetes</i> , 2002, 624-630, Vol. 51.
CS	GAUTIER, C., et al., " α -DNA IV: α -anomeric and β -anomeric Tetrathymidylates Covalently Linked to Intercalating Oxaxolopyridocarbazole. Synthesis, physicochemical properties and poly(rA) Binding," <i>Nucleic Acids Research</i> , 1987, 6625-6641, Vol. 15, No. 16.
CT	GEWIRTZ, A.M., et al., "Developing Oligonucleotide Therapeutics for Human Leukemia," <i>Anti-Cancer Drug Design</i> , 1997, 341-358, Vol. 12.
CU	GOOD, P., et al., "Expression of Small, Therapeutics RNAs in Human Cell Nuclei," <i>Gene Therapy</i> , 1997, 45-54, Vol. 4.
CV	GREEN, et al., "Autonomous Functional Domains of Chemically Synthesized Human Immunodeficiency Virus Tat <i>Trans</i> -Activator Protein," <i>Cell</i> , 1988, 1179-1188, Vol. 55.
CW	GUATELLI, J., et al., Isothermal, <i>In Vitro</i> Amplification of Nucleic Acids by a Multienzyme Reaction Modeled After Retroviral Replication," <i>PNAS USA</i> , 1990, 1874-1878, Vol. 87.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/791,950
Filing Date	March 3, 2004
First Named Inventor	Justin Chapman
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	PC25228A

CX	GUSCHIN, D., et al., "Manual Manufacturing of Oligonucleotide, DNA, and Protein Microchips," <i>Analytical Biochemistry</i> , 1997, 203-211, Vol. 250.
CY	HARA, K., et al., "A Genetic Variation in the PGC-1 Gene Could Confer Insulin Resistance and Susceptibility to Type II Diabetes," <i>Diabetologia</i> , 2002, 740-743, Vol. 45.
CZ	HARTMAN, H., et al., "Mechanisms Regulating Adipocyte Expression of Resistin," <i>Journal of Biological Chemistry</i> , 2002, 19754-19761, Vol. 277, No. 22.
DA	HEALEY, B., et al., "Fiberoptic DNA Sensor Array Capable of Detecting Point Mutations," <i>Analytical Biochemistry</i> , 1997, 270-279, Vol. 251.
DB	HEGDE, P., et al., "A Concise Guide to cDNA Microarray Analysis," <i>Biotechniques</i> , 2000, 548-562, Vol. 29, No. 3.
DC	HELENE, C., et al., "Control of Gene Expression by Triple Helix-Forming Oligonucleotides," <i>Annals New York Academy of Sciences</i> , 1992, 27-36, Vol. 660.
DD	HELENE, C., et al., "The Anti-Gene Strategy: Control of Gene Expression by Triplex-Forming-Oligonucleotides," <i>Anti-cancer Drug Design</i> , 1991, 569-584, Vol. 6.
DE	HERSKOWITZ, I., et al., "Functional Inactivation of Genes by Dominant Negative Mutations," <i>Nature</i> , 1987, 219-222, Vol. 329.
DF	HUANG, J., et al., "Annexin II is Involved in Insulin-Induced GLUT4 Translocation in 3T3-L1 Adipocytes," <i>Diabetes</i> , 2002, 51 (Suppl. 2):A292.
DG	HUANG, J., et al., "Insulin Can Regulate GLUT4 Internalization by Signaling to Rab5 and the Motor Protein Dynein," <i>PNAS USA</i> , 2001, 13084-13089, Vol. 98, No. 23.
DH	HUGHES, T., et al., "Expression Profiling Using Microarrays Fabricated by an Ink-Jet Oligonucleotide Synthesizer," <i>Nature Biotechnology</i> , 2001, 342-347, Vol. 19.
DI	ICHIDA, M., et al., "Identification of a Specific Molecular Repressor of the Peroxisome Proliferator-Activated Receptor γ Coactivator-1 α (PGC-1 α)," <i>Journal of Biological Chemistry</i> , 2002, 50991-50995, Vol. 277, No. 52.
DJ	IMAMURA, T., et al., "G-Alpha-q/11 Protein Plays a Key Role in Insulin-Induced Glucose Transport in 3T3-L1 Adipocytes," <i>Molecular and Cellular Biology</i> , 1999, 6765-6774, Vol. 19, No. 10.
DK	INOUE, H., et al., "Sequence-dependent Hydrolysis of RNA Using Modified Oligonucleotide Splints and RNase H," <i>FEBS Lett.</i> , 1987, 327-330, Vol. 215, No. 2.
DL	INOUE, H., et al., "Synthesis and Hybridization Studies on Two Complementary Nona(2'-O-methyl)ribonucleotides," <i>Nucleic Acids Research</i> , 1987, 6131-6148, Vol. 15, No. 15.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/791,950
Filing Date	March 3, 2004
First Named Inventor	Justin Chapman
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	PC25228A

DM	JENA, P., et al., "Amplification of Genes, Single Transcripts and cDNA Libraries From One Cell and Direct Sequence Analysis of Amplified Products Derived From One Molecule," <i>Journal of Immunological Methods</i> , 1996, 199-213, Vol. 190.
DN	KACHARMINA, J., et al., "Preparation of cDNA from Single Cells and Subcellular Regions," <i>Methods in Enzymology</i> , 1999, 3-18, Vol. 303.
DO	KIM, C.H., et al., "Genomic Variation and Segregation of Equine Infectious Anemia Virus During Acute Infection," <i>Journal of Virology</i> , 1992, 3879-3882, Vol. 66, No. 6.
DP	KIM, S.K., et al., " <i>Pbx1</i> Inactivation Disrupts Pancreas Development and in <i>Ipfl</i> -Deficient Mice Promotes Diabetes Mellitus," <i>Nature Genetics</i> , 2002, 430-435, Vol. 30.
DQ	KLIEWER, S., et al., "Peroxisome Proliferator-Activated Receptors: From Genes to Physiology," <i>Recent Progress in Hormone Research</i> , 2001, 239-263, Vol. 56.
DR	KRUG, M., et al., "First-Strand cDNA Synthesis Primed with Oligo(dT)," <i>Methods in Enzymology</i> , 1987, 316-325, Vol. 152.
DS	KOIZUMI, M., et al., "Design of RNA Enzymes Distinguishing a Single Base Mutation in RNA," <i>Nucleic Acid Research</i> , 1989, 7059-7071, Vol. 17, No. 17.
DT	KOZAL, M., et al., "Extensive Polymorphisms Observed in HIV-1 Clade B Protease Gene Using High-Density Oligonucleotide Arrays," <i>Nature Medicine</i> , 1996, 753-759, Vol. 2, No. 7.
DU	KWOH, D., et al., "Transcription-Based Amplification System and Detection of Amplified Human Immunodeficiency Virus Type 1 With a Bead-Based Sandwich Hybridization Format," <i>PNAS USA</i> , 1989, 1173-1177, Vol. 86.
DV	LANDEGREN, U., et al., "A Ligase-Mediated Gene Detection Technique," <i>Science</i> , 1998, 1077-1080, Vol. 241.
DW	LASHKARI, D., et al., "An Automated Multiplex Oligonucleotide Synthesizer: Development of High-Throughput, Low-Cost DNA Synthesis," <i>PNAS USA</i> , 1995, 7912-7915, Vol. 93.
DX	LATRUFFE, N., et al., "Peroxisome-Proliferator-Activated Receptors as Physiological Sensors of Fatty Acid Metabolism: Molecular Regulation in Peroxisomes," <i>Biochemical Society Transactions</i> , 2001, 305-309, Vol. 29, Part 2.
DY	LEMAITRE, M., et al., "Specific Antiviral Activity of a Poly(l-lysine)-Conjugated Oligodeoxyribonucleotide Sequence Complementary to Vesicular Stomatitis Virus N Protein mRNA Initiation Site," <i>PNAS USA</i> , 1987, 648-652, Vol. 84.
DZ	LETSINGER, R., et al., "Cholesteryl-Conjugated Oligonucleotides: Synthesis, Properties, and Activity as Inhibitors of Replication of Human Immunodeficiency Virus in Cell Culture," <i>PNAS USA</i> , 1989, 6553-6556, Vol. 86.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/791,950
Filing Date	March 3, 2004
First Named Inventor	Justin Chapman
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	PC25228A

EA	LIN, W., et al., "Molecular Scanning of the Human Sorbin and SH3-Domain-Containing-1 (SORBS1) Gene: Positive Association of the T228A Polymorphism with Obesity and Type 2 Diabetes," <i>Human Molecular Genetics</i> , 2001, 1753-1760, Vol. 10, No. 17.
EB	LIVESEY, F., et al., "Microarray Analysis of the Transcriptional Network Controlled By the Photoreceptor Homeobox Gene <i>Crx</i> ," <i>Current Biology</i> , 2000, 301-310, Vol. 10, No. 6.
EC	LOCKHART, D., et al., "Expression Monitoring by Hybridization to High-Density Oligonucleotide Arrays," <i>Nature Biotechnology</i> , 1996, 1675-1680, Vol. 14.
ED	LONG, D., et al., "Self-Cleaving Catalytic RNA," <i>The FASEB Journal</i> , 1993, 25-30, Vol. 7.
EE	LONNROTH, et al., "Insulin Binding and Responsiveness in Fat Cells from Patients with Reduced Glucose Tolerance and Type II Diabetes," <i>Diabetes</i> , 1983, 748-754, Vol. 32.
EF	LUO, L., et al., "Gene Expression Profiles of Laser-Captured Adjacent Neuronal Subtypes," <i>Nature Medicine</i> , 1999, 117-122, Vol. 5, No. 1.
EG	MAHER III, L.J., et al., "DNA Triple-Helix Formation: An Approach to Artificial Gene Repressors?" <i>BioEssays</i> , 1992, 807-815, Vol. 14, No. 12.
EH	MATTILA, P., et al., "Fidelity of DNA Synthesis by the <i>Thermococcus Litoralis</i> DNA Polymerase- an Extremely Heat Stable Enzyme With Proofreading Activity," <i>Nucleic Acids Research</i> , 1991, 4967-4973, Vol. 19, No. 18.
EI	MCGRAW, K., et al., "Antisense Oligonucleotide Inhibitors of Isozymes of Protein Kinase C: <i>In Vitro</i> and <i>In Vivo</i> Activity, and Clinical Development as Anti-Cancer Therapeutics," <i>Anti-Cancer Drug Design</i> , 1997, 315-326, Vol. 12.
EJ	MICHAEL, L., et al., "Restoration of Insulin-Sensitive Glucose Transporter (GLUT4) Gene Expression in Muscle Cells by the Transcriptional Coactivator PGC-1," <i>PNAS USA</i> , 2001, 3820-3825, Vol. 98, No. 7.
EK	MILES, P., et al., "Improved Insulin-Sensitivity in Mice Heterozygous for PPAR- γ Deficiency," <i>Journal of Clinical Investigation</i> , 2000, 287-292, Vol. 105, No. 3.
EL	MONIA, B.P., "First- and Second-Generation Antisense Inhibitors Targeted to Human <i>c-ras</i> Kinase: <i>In Vitro</i> and <i>In Vivo</i> Studies," <i>Anti-Cancer Drug Design</i> , 1997, 327-339, Vol. 12.
EM	NOVAK, J., et al., "Characterization of Variability in Large-Scale Gene Expression Data: Implications for Study Design," <i>Genomics</i> , 2002, 104-113, Vol. 79, No. 1.
EN	NTAMBI, J., et al., "Loss of Stearoyl-CoA Desaturase-1 Function Protects Mice Against Adiposity," <i>PNAS USA</i> , 2002, 11482-86, Vol. 99, No. 17.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). **See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/791,950
Filing Date	March 3, 2004
First Named Inventor	Justin Chapman
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	PC25228A

EO	OHYAMA, H., et al., "Laser Capture Microdissection-Generated Target Sample for High-Density Oligonucleotide Array Hybridization," <i>Biotechniques</i> , 2000, 530-536, Vol. 29.
EP	OJWANG, J., et al., "Inhibition of Human Immunodeficiency Virus Type 1 Expression by a Hairpin Ribozyme," <i>PNAS USA</i> , 1992, 10802-10806, Vol. 89.
EQ	OSMAN, A.A., et al., "Exercise Training Increases ERK2 Activity in Skeletal Muscle of Obese Zucker Rats," <i>Journal of Applied Physiology</i> , 2001, 454-60, Vol. 90.
ER	PEREZ, F., et al., "Antennapedia Homeobox as a Signal for the Cellular Internalization and Nuclear Addressing of a Small Exogenous Peptide," <i>Journal of Cell Science</i> , 1992, 717-722, Vol. 102.
ES	PERROTTA, A., et al., "Cleavage of Oligoribonucleotides by a Ribozyme Derived From the Hepatitis δ Virus RNA Sequence," <i>Biochemistry</i> , 1992, 16-17, Vol. 31.
ET	PIETU, G., et al., "Novel Gene Transcripts Preferentially Expressed in Human Muscles Revealed by Quantitative Hybridization of a High Density cDNA Array," <i>Genome Research</i> , 1996, 492-503, Vol. 6.
EU	POLIARD, A., et al., "Controlled Conversion of an Immortalized Mesodermal Progenitor Cell Towards Osteogenic, Chondrogenic, or Adipogenic Pathways," <i>Journal of Cell Biology</i> , 1995, 1461-1472, Vol. 130, No. 6.
EV	PUIGSERVER, P., et al., "Activation of PPAR γ Coactivator-1 Through Transcription Factor Docking," <i>Science</i> , 1999, 1368-1371, Vol. 286.
EW	RANKI, M., et al., "Sandwich Hybridization as a Convenient Method for the Detection of Nucleic Acids in Crude Samples," <i>Gene</i> , 1983, 77-85, Vol. 21.
EX	REED, J.C. et al., "Promise and Problems of Bcl-2 Antisense Therapy," <i>Journal of the National Cancer Institute</i> , 1997, 988-993, Vol. 89, No. 14.
EY	RIBON, V., et al., "Thiazolidinediones and Insulin Resistance: Peroxisome Proliferator-Activated Receptor γ Activation Stimulates Expression of the CAP Gene," <i>Proc. Natl. Acad. Sci. USA</i> , 1998, 14751-14756, Vol. 95.
EZ	SAKAI, K., et al., "Microarray Hybridization with Fractionated cDNA: Enhanced Identification of Differentially Expressed Genes," <i>Analytical Biochemistry</i> , 2000, 32-37, Vol. 287.
FA	SARIN, P., et al., "Inhibition of Acquired Immunodeficiency Syndrome Virus by Oligodeoxynucleoside Methylphosphonates," <i>Proc. Natl. Acad. Sci. USA</i> , 1988, 7448-7451, Vol. 85.
FB	SARVER, N., et al., "Ribozymes as Potential Anti-HIV-1 Therapeutic Agents," <i>Science</i> , 1990, 1222-1225, Vol. 247.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/791,950
Filing Date	March 3, 2004
First Named Inventor	Justin Chapman
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	PC25228A

FC	SCHENA, M., et al., "Quantitative Monitoring of Gene Expression Patterns With a Complimentary DNA Microarray," <i>Science</i> , 1995, 467-470, Vol. 270.
FD	SCHENA, M., et al., "Microarrays: Biotechnology's Discovery Platform for Functional Genomics," <i>Tibtech</i> , 1998, 301-306, Vol. 16.
FE	SHALON, D., et al., "A DNA Microarray System for Analyzing Complex DNA Samples Using Two-Color Fluorescent Probe Hybridization," <i>Genome Research</i> , 1996, 639-645, Vol. 6.
FF	SHPAER, E., "GeneAssist, Smith-Watermand and Other Datatbase Similarity Searches and Identification of Motifs," <i>Methods of Molecular Biology</i> , 1997, 173-187, Vol. 70, Human Pres Inc., Totawa, NJ.
FG	SHELDON, E., et al., "Matrix DNA Hybridization," <i>Clinical Chemistry</i> , 1993, 718-719, Vol. 39, No. 4.
FH	SPIRIN, K., et al., "Analysis of Gene Expression in Human Bullous Keratopathy Corneas Containing Limiting Amounts of RNA," <i>Investigative Ophtalmology & Visual Science</i> , 1999, 3108-3115, Vol. 40, No. 13.
FI	STEIN, C., et al., "Physicochemical Properties of Phosphorothioate Oligodeoxynucleotides," <i>Nucleic Acids Research</i> , 1988, 3209-3221, Vol. 16, No. 8.
FJ	STEMMER, W., "Rapid Evolution of a Protein <i>In Vitro</i> by DNA Shuffling," <i>Nature</i> , 1994, 389-391, Vol. 370.
FK	STIMPSON, D., et al., "Real-time Detection of DNA Hybridization and Melting on Oligonucleotide Arrays by Using Optical Wave Guides," <i>Proc. Natl. Acad. Sci. USA</i> , 1995, 6379-6383, Vol. 92.
FL	SYMONS, R., et al., "Small Catalytic RNAs," <i>Ann. Rev. Biochem.</i> , 1992, 641-671, Vol. 61
FM	THIEL, A., et al., "In Situ Surface Plasmon Resonance Imaging Detection of DNA Hybridization to Oligonucleotide Arrays on Gold Surfaces," <i>Analytical Chemistry</i> , 1997, 4948-4956, Vol. 69, No. 24.
FN	TIBANYENDA, N., et al., "The Effect of Single Base-Pair Mismatches in the Duplex Stability of d(T-A-T-T-A-A-T-A-T-C-A-A-G-T-T-G) d(C-A-A-C-T-T-G-A-T-A-T-A-T-A)," <i>European Journal of Biochemistry</i> , 1984, 19-27, Vol. 139.
FO	TSAN, M., et al., "Lung-Specific Direct In Vivo Gene Transfer With Recombinant Plasmid DNA," <i>American Journal of Physiology (Lung Cell Mol. Physiol. 12)</i> , (L1052-L1056), 1995, Vol. 268.
FP	TYAGI, S., et al., "Molecular Beacons: Probes that Fluoresce Upon Hybridization," <i>Nature Biotechnology</i> , 1996, 303-308, Vol. 14.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/791,950
Filing Date	March 3, 2004
First Named Inventor	Justin Chapman
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	PC25228A

FQ	USMAN, N., et al., "Hammerhead Ribozyme Engineering," <i>Current Opinion in Structural Biology</i> , 1996, 527-533, Vol. 1.
FR	VAN DER KROL, A., et al., "Modulation of Eukaryotic Gene Expression by Complementary RNA or DNA Sequences," <i>Biotechniques</i> , 1988, 958-976, Vol. 6, No. 10.
FS	VAN GELDER, R., et al., "Amplified RNA Synthesized From Limited Quantities of Heterogeneous cDNA," <i>Proc. Natl. Acad. Sci. USA</i> , 1990, 1663-1667, Vol. 87.
FT	VELCULESCU, V., et al., "Characterization of the Yeast Transcriptome," <i>Cell</i> , 1997, 243-251, Vol. 88.
FU	VELCULESCU, V., et al., "Analysis of Human Transcriptomes," <i>Nature Genetics</i> , 1999, 387-388, Vol. 23.
FV	VELCULESCU, V., et al., "Serial Analysis of Gene Expression," <i>Science</i> , 1995, 484-487, Vol. 270.
FW	WAGNER, M., et al., "Nucleotide Sequence of the Thymidine Kinase Gene of Herpes Simplex Virus Type 1," <i>PNAS USA</i> , 1981, 1441-1445, Vol. 78, No. 3.
FX	WALLACE, R.B., et al., "Hybridization of Synthetic Oligodeoxyribonucleotides to $\phi\chi$ 174 DNA: The Effect of Single Base Pair Mismatch," <i>Nucleic Acids Research</i> , 1979, 3543-3557, Vol. 6, No. 11.
FY	WANG, A., et al., "Quantitation of mRNA by the Polymerase Chain Reaction," <i>PNAS USA</i> , 1989, 9717-9721, Vol. 86.
FZ	WAY, J., et al., "Comprehensive Messenger Ribonucleic Acid Profiling Reveals That Peroxisome Proliferator-Activated Receptor γ Activation Has Coordinate Effects on Gene Expression in Multiple Insulin-Sensitive Tissues," <i>Endocrinology</i> , 2001, 1269-1277, Vol. 142, No. 3.
GA	WILLSON, T., et al., "The PPARs: From Orphan Receptors to Drug Discovery," <i>Journal of Medicinal Chemistry</i> , 2000, 527-550, Vol. 43, No. 4.
GB	WU, D., et al., "The Ligation Amplification Reaction (LAR) - Amplification of Specific DNA Sequences Using Sequential Rounds of Template-Dependent Ligation," <i>Genomics</i> , 1989, 560-569, Vol. 4.
GC	YAMAMOTO, T., et al., "Identification of a Functional Promoter in the Long Terminal Repeat of Rous Sarcoma Virus," <i>Cell</i> , 1980, 787-797, Vol. 22.
GD	YOON, J., et al., "Peroxisome Proliferator-Activated Receptor γ Target Gene Encoding A Novel Angiopoietin-Related Protein Associated with Adipose Differentiation," <i>Molecular and Cellular Biology</i> , 2000, 5343-5349, Vol. 20, No. 14.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/791,950
Filing Date	March 3, 2004
First Named Inventor	Justin Chapman
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	PC25228A

GE	ZHAO, N., et al., "High Density cDNA Filter Analysis: A Novel Approach for Large-Scale Quantitative Analysis of Gene Expression," <i>Gene</i> , 1995, 207-213, Vol. 156.	
GF	ZHANG, L., et al., "Gene Expression Profiles in Normal and Cancer Cells," <i>Science</i> , 1997, 1268-1272, Vol. 276.	
GG	ZON, G., et al., "Oligonucleotide Analogues as Potential Chemotherapeutic Agents," <i>Pharmaceutical Research</i> , 1988, 539-549, Vol. 5, No. 9.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.